News >

Harnessing Immune Response in Advanced Ovarian Cancer

Caroline Seymour
Published: Monday, Aug 05, 2019

Mian M. Shahzad, MD, PhD

Mian M. Shahzad, MD, PhD

Preliminary research has shown that harnessing the immune system can lead to potentially viable and efficacious therapies for patients with advanced ovarian cancer; therefore, combination approaches with checkpoint inhibitors could have an impact on outcomes.

"If we can wake up the immune system to recognize a foreign [entity] and attack it, we may be able to make a big dent in [treatment],” said Mian M. Shahzad, MD, PhD. “There are also ongoing studies with oncolytic virotherapy."

In a presentation during the 2019 OncLive® State of the Science Summit™ on Ovarian Cancer, Shahzad, a gynecologic oncologist in The Center for Women’s Oncology, Moffitt Cancer Center, discussed the use of checkpoint inhibition in advanced ovarian cancer.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Publication Bottom Border
Border Publication
x